Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hoth Therapeutics has reported positive initial data in a Phase IIa clinical trial for one of its programs. Its lead Alzheimer's candidate HT‑ALZ demonstrated significant cognitive and behavioral benefits in preclinical models. The company’s cancer/immunology program HT-KIT has advanced through key preclinical safety studies with plans to enter first-in-human trials. Overall pipeline includes both clinical and late-preclinical assets addressing high unmet needs in neurology, oncology/allergy/inflammation, and dermatology.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hoth Therapeutics.